ClearPoint Neuro, Inc. (CLPT)Healthcare | Medical Devices | Solana Beach, United States | NasdaqCM
15.55 USD
-0.39
(-2.447%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 15.58 +0.03 (0.193%) ⇧ (Aug. 28, 2026, 7:47 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:07 a.m. EDT
The investment case for ClearPoint Neuro is currently fractured by severe execution risks and deteriorating financial health. While the company boasts a 18% revenue growth rate and a recent FDA reversal for its AMT-130 device offers a glimmer of hope, the balance sheet is dangerously impaired. With negative operating cash flow, significant debt, and a return on equity of -226%, the business is burning capital without generating returns. The market has rightly punished this with a 52-week range that has seen the stock halve from its highs, leaving it trading at a premium valuation despite its losses. Short-term, the stock is showing signs of stabilization after a recent dip, with price action holding above key moving averages and some speculative buying interest emerging. However, the statistical forecast models remain weak and bearish, reflecting the uncertainty surrounding the upcoming Q2 earnings report. The options market confirms this anxiety, with traders placing heavy bets on downside protection while waiting for a catalyst to drive a rally. Long-term, the fundamentals are too precarious to justify a buy recommendation. The multi-year trajectory shows a volatile history of gains and losses, capped recently by a year of decline. Without a proven path to profitability or a fortress balance sheet to weather the inevitable regulatory and commercialization hurdles, the risk of permanent capital loss remains high. Investors should wait for clearer evidence of sustainable profitability before committing capital. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.071175 |
| MSTL | 0.100054 |
| AutoTheta | 0.104183 |
| AutoETS | 0.104945 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 0.37 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.672 |
| Excess Kurtosis | -0.39 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 593.411 |
| Revenue per Share | 1.445 |
| Market Cap | 474,340,736 |
| Forward P/E | -14.05 |
| Beta | 1.27 |
| Profit Margins | -81.76% |
| Website | https://www.clearpointneuro.com |
As of Aug. 22, 2026, 4:07 a.m. EDT: Speculators are positioning defensively with heavy put volume at deep strikes ($5, $10) and near-the-money levels, suggesting a fear of further downside or a 'crash' scenario. Conversely, call interest is concentrated at moderate upside targets ($17.50, $20.00, $22.50) rather than aggressive moonshots, indicating a cautious bullish bias that expects a rebound but doubts a massive surge. Implied volatility is elevated on out-of-the-money puts relative to calls, highlighting asymmetric risk concerns.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.52828383 |
| Address1 | 120 S. Sierra Avenue |
| Address2 | Suite 100 |
| All Time High | 200.0 |
| All Time Low | 1.33 |
| Ask | 20.04 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 488,960 |
| Average Daily Volume3 Month | 729,525 |
| Average Volume | 729,525 |
| Average Volume10Days | 488,960 |
| Beta | 1.271 |
| Bid | 11.29 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | 0.353 |
| City | Solana Beach |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 15.55 |
| Current Ratio | 4.745 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 16.08 |
| Day Low | 15.4422 |
| Debt To Equity | 593.411 |
| Display Name | ClearPoint Neuro |
| Dividend Date | 1,469,577,600 |
| Earnings Call Timestamp End | 1,785,789,000 |
| Earnings Call Timestamp Start | 1,785,789,000 |
| Earnings Timestamp | 1,785,787,200 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -28,211,000 |
| Ebitda Margins | -0.66726 |
| Enterprise To Ebitda | -18.04 |
| Enterprise To Revenue | 12.037 |
| Enterprise Value | 508,923,744 |
| Eps Current Year | -1.32333 |
| Eps Forward | -1.10667 |
| Eps Trailing Twelve Months | -1.15 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 15.9756 |
| Fifty Day Average Change | -0.42560005 |
| Fifty Day Average Change Percent | -0.02664063 |
| Fifty Two Week Change Percent | 52.828384 |
| Fifty Two Week High | 30.1 |
| Fifty Two Week High Change | -14.55 |
| Fifty Two Week High Change Percent | -0.4833887 |
| Fifty Two Week Low | 8.27 |
| Fifty Two Week Low Change | 7.2799997 |
| Fifty Two Week Low Change Percent | 0.88029015 |
| Fifty Two Week Range | 8.27 - 30.1 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,337,693,400,000 |
| Float Shares | 26,296,169 |
| Forward Eps | -1.10667 |
| Forward P E | -14.051163 |
| Free Cashflow | -14,050,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 160 |
| Fullday Change | -0.389999 |
| Fullday Change Percent | -2.44667 |
| Fullday Price | 15.58 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.62608004 |
| Gross Profits | 26,470,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.05436 |
| Held Percent Institutions | 0.52424 |
| Implied Shares Outstanding | 30,504,227 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,469,577,600 |
| Last Split Factor | 1:40 |
| Long Business Summary | ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California. |
| Long Name | ClearPoint Neuro, Inc. |
| Market | us_market |
| Market Cap | 474,340,736 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1432648 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -34,566,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 485,322,251 |
| Number Of Analyst Opinions | 3 |
| Open | 15.7 |
| Operating Cashflow | -30,183,000 |
| Operating Margins | -0.94154 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.61 |
| Phone | 888 287 9109 |
| Post Market Change | 0.029999733 |
| Post Market Change Percent | 0.19292432 |
| Post Market Price | 15.58 |
| Post Market Time | 1,787,960,846 |
| Previous Close | 15.94 |
| Price Eps Current Year | -11.750659 |
| Price Hint | 2 |
| Price To Book | 44.050995 |
| Price To Sales Trailing12 Months | 11.219299 |
| Profit Margins | -0.81757003 |
| Quick Ratio | 3.754 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.389999 |
| Regular Market Change Percent | -2.44667 |
| Regular Market Day High | 16.08 |
| Regular Market Day Low | 15.4422 |
| Regular Market Day Range | 15.4422 - 16.08 |
| Regular Market Open | 15.7 |
| Regular Market Previous Close | 15.94 |
| Regular Market Price | 15.55 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 467,525 |
| Return On Assets | -0.24433 |
| Return On Equity | -2.26521 |
| Revenue Growth | 0.181 |
| Revenue Per Share | 1.445 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 30,504,227 |
| Shares Percent Shares Out | 0.14739999 |
| Shares Short | 4,496,450 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,695,062 |
| Short Name | ClearPoint Neuro Inc. |
| Short Percent Of Float | 0.1525 |
| Short Ratio | 7.17 |
| Source Interval | 15 |
| State | CA |
| Symbol | CLPT |
| Target High Price | 30.0 |
| Target Low Price | 22.0 |
| Target Mean Price | 25.66667 |
| Target Median Price | 25.0 |
| Total Cash | 29,363,000 |
| Total Cash Per Share | 0.963 |
| Total Debt | 63,946,000 |
| Total Revenue | 42,279,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.15 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 13.4575 |
| Two Hundred Day Average Change | 2.0924997 |
| Two Hundred Day Average Change Percent | 0.15548947 |
| Type Disp | Equity |
| Volume | 467,525 |
| Website | https://www.clearpointneuro.com |
| Zip | 92,075 |